Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2015

View Archived Issues

Anti-annexin II shows potential as a new biomarker for APS

Resverlogix closes license agreement, enters stock purchase agreement with Hepalink

Monopar partners with Cancer Research UK and Cancer Research Technology on HuATN-658

Allergan patents EP2 receptor agonists

Daiichi Sankyo describes LCAT activators

Sanofi reports dual GIPR/GLP-1R agonists

Sunovion Pharmaceuticals reports P2X4 negative modulators

Bristol-Myers Squibb presents HCV NS5B inhibitors

Epizyme and Celgene extend research collaboration

AstraZeneca divests global rights to Entocort

CB-5083 receives FDA orphan drug designation for multiple myeloma

FDA orphan drug designation granted to Rett's syndrome candidate sarizotan

Etodolac and propranolol combination receives U.S. orphan status for malignant glioma

Genentech's atezolizumab reduces tumor size in phase II urothelial bladder cancer study

sFLT-1 may enable early diagnosis of sickle cell nephropathy

FDA approves Rexulti for schizophrenia and major depressive disorder

Homocitrulline can differentiate acute and chronic renal failure

Canadian trial investigates novel tumor-targeted oncolytic virus vaccine

BioDiem and Griffith University receive grant to study targets of BDM-I

Galectin-3 may be a biomarker of cirrhosis severity

Imbruvica approved in E.U. for Waldenstrom's macroglobulinemia

The Scripps Research Institute to study environmental triggers for autoimmune disease

Novel hyaluronic acid eyedrops promote corneal tissue healing

Benitec acquires full rights to Hepbarna hepatitis B program

Novo Nordisk releases results from first phase IIIa study of semaglutide for type 2 diabetes

EyeGate licenses EGP-437 and delivery technology to Valeant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...